KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Other financing activities (2017 - 2025)

Historic Other financing activities for Inovio Pharmaceuticals (INO) over the last 11 years, with Q3 2025 value amounting to -$1787.0.

  • Inovio Pharmaceuticals' Other financing activities rose 7215.64% to -$1787.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$110783.0, marking a year-over-year increase of 7367.29%. This contributed to the annual value of -$420795.0 for FY2024, which is 982.56% up from last year.
  • As of Q3 2025, Inovio Pharmaceuticals' Other financing activities stood at -$1787.0, which was up 7215.64% from -$34777.0 recorded in Q2 2025.
  • In the past 5 years, Inovio Pharmaceuticals' Other financing activities registered a high of -$1787.0 during Q3 2025, and its lowest value of -$4.6 million during Q4 2021.
  • For the 4-year period, Inovio Pharmaceuticals' Other financing activities averaged around -$560957.2, with its median value being -$54498.0 (2025).
  • As far as peak fluctuations go, Inovio Pharmaceuticals' Other financing activities plummeted by 64361.76% in 2024, and later surged by 8551.74% in 2025.
  • Over the past 4 years, Inovio Pharmaceuticals' Other financing activities (Quarter) stood at -$4.6 million in 2021, then skyrocketed by 99.79% to -$9650.0 in 2023, then soared by 33.49% to -$6418.0 in 2024, then skyrocketed by 72.16% to -$1787.0 in 2025.
  • Its last three reported values are -$1787.0 in Q3 2025, -$34777.0 for Q2 2025, and -$74219.0 during Q1 2025.